Answers are grounded in this paper and cite their sources.
No AccessJournal of UrologyClinical Urology: Original Articles1 Oct 1998THE IMPACT OF MEDICAL THERAPY ON BOTHER DUE TO SYMPTOMS, QUALITY OF LIFE AND GLOBAL OUTCOME, AND FACTORS PREDICTING RESPONSE HERBERT LEPOR, WILLIAM O. WILLIFORD, MICHAEL J. BARRY, CLAIR HAAKENSON, and KAREN JONES HERBERT LEPORHERBERT LEPOR , WILLIAM O. WILLIFORDWILLIAM O. WILLIFORD , MICHAEL J. BARRYMICHAEL J. BARRY , CLAIR HAAKENSONCLAIR HAAKENSON , and KAREN JONESKAREN JONES View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)62536-9AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We determine the effect of placebo, finasteride, terazosin and a combination of drugs on bother due to symptoms, quality of life and patient perception of improvement, and identify baseline clinical factors that predict clinical response to medical therapy. Materials and Methods: A total of 1,229 subjects with clinical benign prostatic hyperplasia (BPH) were randomized to 1 year of placebo, finasteride, terazosin or drug combination. The primary outcome measures were American Urological Association (AUA) symptom score and peak flow rate. Relevant secondary outcome measures were symptom problem score, BPH impact score and global rating of improvement. Results: Group mean differences in symptom problem and BPH impact scores between the finasteride versus placebo, and terazosin versus combination groups were not statistically or clinically significant. Group mean differences in all outcome measures were highly statistically significant between the terazosin and finasteride, and combination and finasteride groups. The percentage of subjects who rated improvement as marked or moderate with placebo, finasteride, terazosin and combination was 39, 44, 61 and 65%, respectively. In the subsets of men in the placebo, finasteride, terazosin and combination groups with prostates greater than 50 cm.3 group mean decrease from baseline in AUA symptom score was -2.5, -3.6, -6 and -7, group mean increase in peak flow rate was 0.6, 2.7, 3.6 and 3.7 ml. per second, group mean decrease in symptom problem score was -2.2, -1.9, -3.1 and -4.5, and group mean decrease in BPH impact score was -0.6, -0.3, -1.1 and -1.5, respectively. A correlational analysis failed to show a significant relationship between baseline prostate volume and treatment response to finasteride. There was a significant but weak relationship between change in AUA symptom score and peak flow rate in the finasteride and combination groups. The symptom responses with terazosin were independent of baseline peak flow rate. Conclusions: In men with clinical BPH finasteride and placebo are equally effective, while terazosin and combination are significantly more effective. In men with clinical BPH and large prostates the advantage of finasteride over placebo in terms of symptom reduction, impact on bother due to symptoms and quality of life is small at best, while the advantage of terazosin and combination over finasteride and placebo is highly significant. Baseline prostate volume was not a predictor of response to finasteride in the overall study population. On the basis of our results alpha 1 blockers, such as terazosin, should be first line medical treatment for BPH. References 1 : Alpha blockade for the treatment of benign prostatic hyperplasia. Urol. Clin. N. Amer.1995; 22: 375. Google Scholar 2 : Medical therapy for benign prostatic hyperplasia. Urology1993; 42: 483. Google Scholar 3 : Benign prostatic hyperplasia hormonal treatment. Urol. Clin. N. Amer.1995; 22: 387. Google Scholar 4 : Natural history, evaluation and nonsurgical management of benign prostatic hyperplasia. In: . Philadelphia: W.B. Saunders1998: 1453. chapt 47. Google Scholar 5 : Pathophysiology of clinical benign prostatic hyperplasia. Urol. Clin. N. Amer.1995; 22: 285. Google Scholar 6 : A randomized multicenter placebo controlled study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J. Urol.1992; 148: 1467. Abstract, Google Scholar 7 : Terazosin in the treatment of benign prostatic hyperplasia. Arch. Fam. Med.1993; 2: 929. Google Scholar 8 : A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology1996; 47: 335. Google Scholar 9 : Hytrin community assessment trial (HYCAT): evaluation of the clinical effectiveness of terazosin versus placebo in the treatment of patients with symptomatic benign prostatic hyperplasia. J. Urol.1995; 153: 272A. abstract 175. Google Scholar 10 : A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Brit. J. Urol.1994; 74: 50. Google Scholar 11 : Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled dose response multicenter study. J. Urol.1995; 154: 110. Abstract, Google Scholar 12 : Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J. Urol.1995; 154: 105. Link, Google Scholar 13 : Use of an alpha 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J. Urol.1990; 144: 908. Abstract, Google Scholar 14 : Tamsulosin, a selective alpha1cadrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic obstruction. Brit. J. Urol.1995; 76: 325. Google Scholar 15 : Clinical evaluation of tamsulosin, a prostate selective alpha1cantagonist. J. Urol.1995; 153: 274A. abstract 182. Google Scholar 16 : Dose ranging study of the antiandrogen flutamide in men with benign prostatic hyperplasia (BPH): effect on prostate volume and serum prostate specific antigen (PSA) level. J. Urol.1996; 155: 575A. abstract 1059. Google Scholar 17 : The effect of zanoterone, a steroidal androgen receptor antagonist, in men with benign prostatic hyperplasia. J. Urol.1995; 154: 1060. Abstract, Google Scholar 18 : The effect of finasteride in men with benign prostatic hyperplasia. New Engl. J. Med.1992; 327: 1185. Google Scholar 19 : Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate1993; 22: 291. Google Scholar 20 : Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology1995; 46: 631. Google Scholar 21 : The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. New Engl. J. Med.1996; 335: 533. Google Scholar 22 : Measuring disease-specific health status in men with benign prostatic hyperplasia. Med. Care1995; 33: AS145. Google Scholar 23 : The American Urological Association symptom index for benign prostatic hyperplasia. J. Urol.1992; 148: 1549. Abstract, Google Scholar 24 : Advances in benign prostatic hyperplasia. The developmental and clinical utility of symptom scores. Urol. Clin. N. Amer.1995; 22: 299. Google Scholar 25 : Sonographic measurements of transition zone of prostate in men with and without benign prostatic hyperplasia. Urology1990; 36: 293. Google Scholar 26 : BMDP-5V unbalanced repeated measures models with structured covariance matrices. Technical Report Number 86. Los Angeles: BMDP Statistical Software1988. Google Scholar 27 : Simultaneous Statistical Inference. New York: McGraw-Hill1960. Google Scholar 28 : Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology1966; 48: 398. Google Scholar 29 : Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J. Urol.1995; 153: 1510. Link, Google Scholar 30 : International Prostate Symptom Score and quality of life assessment versus urodynamic parameters in men with benign prostatic hyperplasia symptoms. J. Urol.1995; 153: 1516. Link, Google Scholar 31 : Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J. Urol.1993; 150: 351. Link, Google Scholar 32 : Transition zone index as a method of assessing benign prostatic hyperplasia: Correlation with symptoms, urine flow and detrusor pressure. J. Urol.1995; 154: 1764. Link, Google Scholar 33 : The development of human prostatic hyperplasia with age. J. Urol.1984; 132: 474. Abstract, Google Scholar 34 : Benign prostatic hyperplasia specific health status measures in clinical research: How much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J. Urol.1995; 154: 1770. Abstract, Google Scholar 35 : Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates. Urology1997; 49: 476. Google Scholar 36 : The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. New Engl. J. Med.1998; 328: 557. Google Scholar For the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group; From the Veterans Affairs Medical Center and New York University Medical Center, New York, New York, Cooperative Studies Program Coordinating Center, Veterans Affairs Medical Center, Perry Point, Maryland, Medical Practices Evaluation Center and Massachusetts General Hospital, Boston, Massachusetts, Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Veterans Affairs Medical Center, Albuquerque, New Mexico, and Veterans Affairs Medical Center, Milwaukee, Wisconsin© 1998 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byFwu C, Eggers P, Kaplan S, Kirkali Z, Lee J and Kusek J (2018) Long-Term Effects of Doxazosin, Finasteride and Combination Therapy on Quality of Life in Men with Benign Prostatic HyperplasiaJournal of Urology, VOL. 190, NO. 1, (187-193), Online publication date: 1-Jul-2013.Goi Y, Tomiyama Y, Nomiya M, Sagawa K, Aikawa K and Yamaguchi O (2018) Effects of Silodosin, a Selective α1A-Adrenoceptor Antagonist, on Bladder Blood Flow and Bladder Function in a Rat Model of Atherosclerosis Induced Chronic Bladder Ischemia without Bladder Outlet ObstructionJournal of Urology, VOL. 190, NO. 3, (1116-1122), Online publication date: 1-Sep-2013. (2018) AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment RecommendationsJournal of Urology, VOL. 170, NO. 2, (530-547), Online publication date: 1-Aug-2003.Albrecht M, Gillen S, Wilhelm B, Doroszewicz J and Aumüller G (2018) Expression, Localization and Activity of Neutral Endopeptidase in Cultured Cells of Benign Prostatic Hyperplasia and Prostate CancerJournal of Urology, VOL. 168, NO. 1, (336-342), Online publication date: 1-Jul-2002.BARRY M, WILLIFORD W, FOWLER F, JONES K and LEPOR H (2018) FILLING AND VOIDING SYMPTOMS IN THE AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX: THE VALUE OF THEIR DISTINCTION IN A VETERANS AFFAIRS RANDOMIZED TRIAL OF MEDICAL THERAPY IN MEN WITH A CLINICAL DIAGNOSIS OF BENIGN PROSTATIC HYPERPLASIAJournal of Urology, VOL. 164, NO. 5, (1559-1564), Online publication date: 1-Nov-2000. Volume 160Issue 4October 1998Page: 1358-1367 Advertisement Copyright & Permissions© 1998 by American Urological Association, Inc.MetricsAuthor Information HERBERT LEPOR More articles by this author WILLIAM O. WILLIFORD More articles by this author MICHAEL J. BARRY More articles by this author CLAIR HAAKENSON More articles by this author KAREN JONES More articles by this author Expand All Advertisement PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Lepor et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: